A 24‐week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of Alzheimer's disease
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: The lipoprotein‐associated phospholipase A 2 inhibitor (Lp‐PLA 2 ), rilapladib (SB659032), is being evaluated as a potential treatment to slow the progression of Alzheimer's disease (AD). Methods: One hundred twenty‐four subjects with possible mild AD and with neuroimaging evidence of cerebrovascular disease were randomized to placebo or 250‐mg rilapladib once daily, for 24 weeks, in addition to stable background acetylcholinesterase inhibitor and/or memantine. The study assessed the safety and tolerability of rilapladib and its effects on cognition, mechanistic, and disease‐related biomarkers. Although the overall intent behind the study was to take a broad exploratory view of the data, two primary end points of interest (cerebrospinal fluid [CSF] amyloid beta peptide 1–42 [Aβ 1–42 ] and CogState executive function/working memory [EF/WM] composite score at week 24) were prespecified in the analysis plan for inferential statistical analysis. Results: Rilapladib was well tolerated with no significant safety concerns. A significant difference from placebo was observed for rilapladib on change from baseline in EF/WM (effect size, 0.45; P = .026). There was no significant difference between groups on the change from baseline in CSF Aβ 1–42 ( P = .133). Preliminary evidence of effects was detected on other mechanistic (albumin quotient) and disease‐related biomarkers (tau/P‐tau and neurofilament light chain). Conclusion: These data provide initial evidence supporting Lp‐PLA 2 inhibition as a novel treatment for dementia. Clinical Trial Registration: Clinicaltrials.gov identifier: NCT01428453 .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2001) · The Lancet · doi:10.1016/s0140-6736(00)03589-3 · Cited by 1,338
Blood–brain barrier: Ageing and microvascular disease – systematic review and meta-analysis
Farrall, A. J., & Wardlaw, J. M. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.07.015 · Cited by 882
The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia
Iadecola, C. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0718-6 · Cited by 557
Total and phosphorylated tau protein as biological markers of Alzheimer’s disease
Hampel, H., Blennow, K., Shaw, L. M., Hoessler, Y. C., Zetterberg, H., & Trojanowski, J. Q. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2009.10.010 · Cited by 389 · cited 2×
“Tau and P-tau are considered measures of neuronal damage and neurodegeneration, and both biomarkers are increased early in the disease and remain elevated during the course of the disease [27].”
BackgroundResultVascular pathology in the aged human brain
Grinberg, L. T., & Thal, D. R. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0652-7 · Cited by 345
Bjerke, M., Zetterberg, H., Edman, Å., Blennow, K., Wallin, A., & Andreasson, U. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110566 · Cited by 180 · cited 1×
“NF-L was assessed as an exploratory measure of white matter (axonal) damage, as it has been reported to be increased in some forms of dementia with subcortical involvement [28] and in demyelinating diseases, such as multiple sclerosis where treatmentrelated reductions in this marker have been noted [29].”
BackgroundEsiri, M. M., Joachim, C., Sloan, C., Christie, S., Agacinski, G., Bridges, L. R., Wilcock, G. K., & Smith, A. D. (2014) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31829b72f1 · Cited by 42
Cited by
Investigation of a Bicyclo[1.1.1]pentane as a Phenyl Replacement within an LpPLA 2 Inhibitor
Measom, N. D., Down, K. D., Hirst, D. J., Jamieson, C., Manas, E. S., Patel, V. K., & Somers, D. O. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00281 · Cited by 253
Lipoprotein‐associated phospholipase A2: The story continues
Huang, F., Wang, K., & Shen, J. (2020) · Medicinal Research Reviews · doi:10.1002/med.21597 · Cited by 212
“based on the preclinical data of GSK and that of our group but shows therapeutic effects on AD, suggesting a mediating mechanism by peripheral tissue.(21) Therefore, whether brain tissue can secrete Lp‐PLA2 and what the biological functions of brain‐derived Lp‐PLA2 are remain to be established.”
BackgroundMethodHe, S., Xu, Z., & Han, X. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00803-6 · Cited by 62
Zimetti, F., Adorni, M. P., Marsillach, J., Marchi, C., Trentini, A., Valacchi, G., & Cervellati, C. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6695796 · Cited by 49
“These findings were the source of inspiration for a successive randomized, double-blind, placebocontrolled study on subjects with possible mild AD and with neuroimaging evidence of cerebrovascular disease [98].”
Background
Metadata
- Authors
- Maher‐Edwards, G., De'Ath, J., Barnett, C., Lavrov, A., & Lockhart, A.
- Venue
- Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Publisher
- Wiley
- Published
- 2015-06-29
- Volume
- 1
- Issue
- 2
- Pages
- 131-140
- ISSN
- 2352-8737 (ISSN-L)
- OpenAlex
- W2129442979
- Cited by
- 54
- References
- 7
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.